Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...

SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...

The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, however, committed to progressing its remaining pipeline of candidates for ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology ...

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

RAAINBOW-2 is an international, double-blind, placebo-controlled Phase 3 study for the treatment of moderate to severe alopecia areata (AA) in at least 500 subjects. -- Cinainu is the first topical ...

Johnson & Johnson's phase 2b study of a treatment of moderate to severe atopic dermatitis will end early after the results didn't meet its efficacy standards. The company said the results of a planned ...

On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with ...

Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.